Enterprise Value
-8.679M
Cash
669.3M
Avg Qtr Burn
-50.99M
Short % of Float
10.07%
Insider Ownership
11.04%
Institutional Own.
81.57%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Latozinemab (AL001) (progranulin) Details Frontotemporal dementia with a granulin mutation, Dementia | Phase 3 Data readout | |
AL002 (TREM 2) Details Alzheimer's disease | Phase 2 Data readout | |
Latozinemab (AL001) (progranulin) Details Frontotemporal dementia with C9orf72 mutation, Dementia, Chronic kidney disease, Kidney disease, Amyotrophic lateral sclerosis | Phase 2 Data readout | |
AL101 (Progranulin) Details Alzheimer's disease, Parkinson's disease, Neurological disorder | Phase 2 Initiation | |
AL003 (SIGLEC 3) Details Alzheimer's disease | Failed Discontinued |